Nuvectis Pharma reports Q1 2026 loss of $6.1M, advances NXP900 cancer drug trials with data expected in summer.

Nuvectis Pharma reported a net loss of $6.1 million for Q1 2026, slightly higher than the previous year, while continuing patient enrollment in its NXP900 Phase 1b clinical trial for cancer treatment. The company highlighted promising preclinical data showing synergy of NXP900 combined with sotorasib in lung cancer models. With $25.1 million in cash, Nuvectis expects preliminary clinical data this summer and remains focused on advancing its oncology drug development with financial discipline.